Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05788289 · ClinicalTrials.gov registry record · Phase 2
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT05788289: Clinical Trial Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05788289 is a Phase 2 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05788289, a Phase 2 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of tafasitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma.
Interventions
- DRUG Lenalidomide
- DRUG Tafasitamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-03-14 |
| Est. Completion | 2024-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05788289
The ClinicalTrials.gov registry entry for NCT05788289 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT05788289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05788289 about?
NCT05788289 is a clinical study titled "A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma". The purpose of this study is to determine if the combination of tafasitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma.
What is the current status of trial NCT05788289?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2023-03-14. Estimated completion is 2024-08-01.
What interventions are being tested in trial NCT05788289?
The interventions under investigation include: Lenalidomide (DRUG), Tafasitamab (DRUG).
Who is sponsoring clinical trial NCT05788289?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.